AbbVie Call Options Surge 2,599% Amid Q4 Earnings Anticipation

domingo, 18 de enero de 2026, 2:38 am ET1 min de lectura
ABBV--

AbbVie's call options surged 2,599%, indicating institutional investors are betting on a positive Q4 earnings report and long-term growth in the metabolic health and obesity markets. The company has a history of exceeding analyst estimates and has successfully transitioned from Humira to other drugs like Skyrizi and Rinvoq. A comprehensive federal agreement also ensures the organization can focus on research and domestic manufacturing.

AbbVie Call Options Surge 2,599% Amid Q4 Earnings Anticipation

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios